Get the Stockscreener App
30.10
2.14%
0.63
After Hours:
30.12
0.02
+0.07%
Alkermes Plc stock is traded at $30.10, with a volume of 1.33M.
It is up +2.14% in the last 24 hours and up +1.31% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$29.47
Open:
$29.81
24h Volume:
1.33M
Relative Volume:
0.86
Market Cap:
$5.09B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
15.44
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
+5.61%
1M Performance:
+1.31%
6M Performance:
+21.22%
1Y Performance:
+7.89%
1-Day Range:
$29.68
$30.15
1-Week Range:
$28.28
$30.15
52-Week Range:
$22.90
$32.88
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.10 | 5.09B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
With nearly $1B in the bank, Alkermes is on the hunt for deals - The Business Journals
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 14.1% - MarketBeat
Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price - Simply Wall St
(ALKS) Proactive Strategies - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Holdings Trimmed by JPMorgan Chase & Co. - MarketBeat
Zacks Research Reduces Earnings Estimates for Alkermes - MarketBeat
What is Zacks Research's Forecast for Alkermes Q2 Earnings? - MarketBeat
Alkermes plc (NASDAQ:ALKS) Receives $36.00 Average PT from Brokerages - MarketBeat
Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Alkermes CEO to Present Corporate Strategy at J.P. Morgan Healthcare Conference 2025 - StockTitan
Alkermes to Report Third Quarter Financial Results on October 24, 2024 - Quantisnow
Declining Stock and Solid Fundamentals: Is The Market Wrong About Alkermes plc (NASDAQ:ALKS)? - Yahoo Finance
Alkermes plc (NASDAQ:ALKS) Sees Large Decrease in Short Interest - MarketBeat
Principal Financial Group Inc. Has $24.57 Million Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
(ALKS) On The My Stocks Page - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Stake Boosted by Sanctuary Advisors LLC - MarketBeat
Expansion Therapeutics Names Elliot Ehrich, MD, Chief Medical Officer - Marketscreener.com
Alkermes pays off and terminates major credit agreement By Investing.com - Investing.com Canada
2025 will be a big year for Mural Oncology's drugs in development - The Business Journals
Alkermes pays off and terminates major credit agreement - Investing.com
Alkermes Prepares for New Flexibility Post Credit Termination - TipRanks
Tidal Investments LLC Takes Position in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Geode Capital Management LLC Sells 60,037 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt - Simply Wall St
Wilmington Savings Fund Society FSB Invests $582,000 in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Barclays PLC Boosts Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes To Take Part In The Fourth Annual Evercore ISI Healthconx Conference - Environmental Expert
Opioid Use Disorder Market: Share, Key Trends, Growth Drivers, - openPR
When (ALKS) Moves Investors should Listen - Stock Traders Daily
Fmr LLC Has $9.71 Million Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
State Street Corp Lowers Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million By Investing.com - Investing.com South Africa
Frazier Life Sciences Management L.P. Acquires New Stake in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes director Cato Laurencin sells $85,708 in stock - Investing.com India
Alkermes director Cato Laurencin sells $85,708 in stock By Investing.com - Investing.com Canada
Alkermes' EVP Craig Hopkinson sells shares worth $1.96 million - Investing.com
Wellington Management Group LLP Sells 1,696,507 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Stake Lifted by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Insider Sell: Craig Hopkinson Sells 9,221 Shares of Alkermes PLC (ALKS) - GuruFocus.com
Alkermes' chief medical officer sells $290,461 in stock - Investing.com India
Alkermes' chief medical officer sells $290,461 in stock By Investing.com - Investing.com UK
Insider Sell: Craig Hopkinson Sells 14,349 Shares of Alkermes PL - GuruFocus.com
RTW Investments LP Sells 402,955 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
BNP Paribas Financial Markets Buys 63,939 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes EVP and chief medical officer sells shares worth $441,550 By Investing.com - Investing.com Canada
Alkermes EVP and chief medical officer sells shares worth $441,550 - Investing.com
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):